Email This Article

Endo Pharmaceuticals Falls on Disappointing Trial Results
By Meredith Derby
10/28/02 - 02:45 PM EST
Its product is unable to improve on the pain-relieving qualities of morphine.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)
Dow Jones S&P 500 NASDAQ 10-Year Note
10,406.96 1,109.30 2,197.85 33.31
Oil *
78.75
UP
136.49
UP
15.82
UP
29.97
DOWN
0.98
10 Yr
3.33%
SPDR Gold
111.63
+1.33%
+1.45%
+1.38%
-2.86%
Data delayed 20 minutes

Brokerage Partners